



## Traditional African Medicinal Plants as Potential Sources of Anticancer Agents: Bioactive Compounds, Mechanisms, and Future Directions

Mbah, C.A <sup>a</sup>, Okonkwo, S.C <sup>a</sup>, Nwaume, E.J <sup>a</sup>, Olawoore, F.R <sup>b</sup> & Abah, E.I <sup>a</sup>

<sup>a</sup> Science Laboratory Technology (Biochemistry), Institute of Management and Technology, Enugu State, Nigeria

<sup>b</sup> Crop and Environmental Protection, Ladoke Akintola University of Technology, Ogbomosho, Oyo State, Nigeria

### ABSTRACT:

Cancer remains a leading cause of mortality worldwide, necessitating the continuous search for novel and effective therapeutic agents. Traditional African medicinal plants, long utilized in indigenous healthcare systems, represent a rich reservoir of bioactive compounds with promising anticancer properties. This review comprehensively explores the anticancer potential of selected African medicinal plants, highlighting their phytochemical constituents, mechanisms of action, and therapeutic relevance. Specific emphasis is placed on compounds such as alkaloids, flavonoids, terpenoids, and phenolics that exhibit cytotoxicity, apoptosis induction, cell cycle arrest, and inhibition of metastasis. The article also examines current limitations in research, including standardization, clinical validation, and bioprospecting challenges. By integrating traditional knowledge with modern pharmacological approaches, these medicinal plants may serve as viable leads for anticancer drug development. Further scientific investigation and clinical validation are imperative to translate these ethnobotanical insights into effective anticancer therapies.

**Keywords:** Traditional medicine, African medicinal plants, anticancer agents, phytochemicals, apoptosis, cancer therapy, drug discovery, ethnopharmacology.

### Introduction

Cancer remains one of the most significant global health challenges of the 21st century, accounting for nearly 10 million deaths worldwide in 2020 and disproportionately affecting low- and middle-income countries, including those in Africa [1,2]. In sub-Saharan Africa alone, there were over 800,000 new cases and more than 520,000 deaths in 2020, with breast, cervical, prostate, and liver cancers being the most common types [3]. The increasing burden of cancer in Africa is compounded by limited access to early diagnosis, effective treatment, and chemotherapy, which remains both expensive and often unavailable to the majority of the population [4, 5–7].

Historically, conventional cancer treatments such as surgery, radiotherapy, and chemotherapy have significantly improved patient survival, particularly in high-income countries [8, 9]. However, these therapies are frequently associated with severe side effects, development of multidrug resistance, and reduced quality of life. This has fueled the growing interest in complementary and integrative oncology approaches that incorporate natural products, particularly those derived from medicinal plants [10, 11]. Notably, the discovery of plant-based anticancer drugs such as vinblastine and vincristine from *Catharanthus roseus*, and paclitaxel from *Taxus brevifolia*, highlights the immense therapeutic potential of phytochemicals [10].

African traditional medicine, which has long served as a primary healthcare resource for over 80% of the population [12], represents a largely untapped reservoir of bioactive compounds with anticancer properties. Rich in chemical diversity alkaloids, flavonoids, terpenoids, phenolics, and steroids—these plants exhibit multiple mechanisms of action including the induction of apoptosis, inhibition of cell proliferation, modulation of oncogenic signaling pathways, and reduction of oxidative stress [13, 14, 15]. Importantly, many of these compounds demonstrate selective cytotoxicity, targeting malignant cells while sparing healthy ones [15].

Despite the widespread ethnomedical use of African plants for cancer treatment and their promising pharmacological profiles, systematic research on their active constituents, molecular mechanisms, and clinical potential remains limited. The variability in regional practices, types of plants used, and extraction protocols further underscores the need for structured investigation and documentation [16].

This review aims to bridge this knowledge gap by critically analyzing existing literature on African medicinal plants with reported anticancer activity. It focuses on their phytochemical constituents, underlying cellular and molecular mechanisms, and outlines future directions for preclinical and clinical studies. By consolidating current evidence, this work advocates for the scientific validation of traditional African medicinal knowledge, with the ultimate goal of contributing to the global fight against cancer through the development of safe, affordable, and accessible plant-derived therapeutics.

## Overview of African Medicinal Plants with Anticancer Potential

Natural products have long played a central role in the development of pharmaceutical agents. Remarkably, over 25% of current therapeutics used to treat human diseases are plant-derived, while another 25% are modified forms of natural products [17]. Among these, polyphenols—abundant in fruits and vegetables—are particularly valued for their chemopreventive and therapeutic roles in oncology. Many anticancer drugs are either direct plant extracts or semi-synthetic derivatives of plant-based compounds. For instance, etoposide (VP-16), a well-known anticancer agent, is derived semi-synthetically from podophyllotoxin, a lignan sourced from *Podophyllum* species [18].

Approximately 60% of currently available anticancer medications are rooted in natural product chemistry, with plants contributing significantly. Notable examples include the vinca alkaloids, taxanes (such as taxol and docetaxel), camptothecin, and combretastatin [19]. The process of identifying these agents typically begins with in vitro screening for cytotoxic or cytostatic activity on cancer cell lines, often guided by traditional medicinal knowledge or ethnobotanical databases [18].

Among African nations, Nigeria stands out as a key contributor to research on medicinal plants with anticancer potential, underscoring the region's rich biodiversity and traditional medicinal heritage.

- ***Dicoma anomala***

A member of the Asteraceae family, *Dicoma anomala* commonly referred to as the fever or stomach bush is a perennial herb native to sub-Saharan Africa. It is widely distributed across various South African provinces and has been traditionally employed to treat ailments such as fevers, ulcers, coughs, and diabetes [20]. The roots and leaves of *D. anomala* contain bioactive compounds including flavonoids, phenolic acids, phytosterols, sesquiterpenes, and triterpenes, many of which exhibit anticancer effects without harming normal cells.

Notably, extracts from *D. anomala* have demonstrated antiproliferative effects against breast cancer cell lines (MCF-7), particularly when sesquiterpenes are conjugated to silver nanoparticles [21]. Similarly, aqueous extracts of *Dicoma capensis*, a related species, have shown anticancer activity against breast cancer lines such as MDA-MB-231 and MCF-12A [22]. These findings validate traditional uses and position *Dicoma* species as valuable candidates for anticancer drug discovery.

- ***Fagaropsis angolensis***

Belonging to the Rutaceae family, *Fagaropsis angolensis* is distributed across central and eastern Africa. It is a deciduous tree traditionally used in ethnomedicine and has recently garnered attention for its anticancer properties. Methanol extracts from its root and stem have shown cytotoxic effects against various cancer cell lines including Hep2 (throat), CT26 (colon), DU-145 (prostate), and HCC1395 (breast), with impressive IC<sub>50</sub> values as low as 5.25 µg/ml [23,24,25].

However, despite its potent anticancer effects, *F. angolensis* has also shown cytotoxicity against normal Vero cells, indicating a narrow therapeutic index. This underscores the need for further pharmacological studies to isolate, standardize, and optimize the dosage of its active compounds to reduce toxicity while maintaining efficacy.

- ***Withania somnifera***

Widely recognized as Ashwagandha, *Withania somnifera* is a small evergreen shrub found in parts of southern Africa, including Botswana and South Africa. It belongs to the Solanaceae family and is rich in bioactive compounds, particularly withanolide and withaferin A, which are credited for its anticancer properties.

These compounds have been shown to inhibit vimentin, a marker of metastasis, thereby impeding tumor progression, especially in breast cancer models [26]. In vivo studies in murine models revealed that *W. somnifera* modulates apoptosis, autophagy, and oxidative stress pathways [27]. Its ethanol root extracts have been reported to inhibit A549 lung cancer cells by downregulating PI3K, a key player in metastasis [28]. Moreover, earlier findings noted its protective effects against ROS-induced damage and lung adenoma in mice [29].

- ***Prunus Africana***

*Prunus africana*, a tree found in Southern and Central Africa, has been traditionally used to treat prostate cancer [30, 31]. Studies show its bark extracts reduce prostate cancer growth by inducing apoptosis in prostate cancer cells [24]. Bioactive compounds such as β-amyrin and β-sitosterol contribute to its anticancer effects [32]. However, due to its endangered status, a micropropagation protocol has been developed for future use in drug development [33].

- ***Securidaca longipedunculata***

*Securidaca longipedunculata*, known for its use in treating cancer in Northern Nigeria, shows antiproliferative effects in vitro and in vivo by inhibiting angiogenesis and inducing apoptosis [34,35]. The active compounds, including xanthenes, have been shown to target tumor cells and inhibit cell proliferation [36,37].

- ***Annona senegalensis***

Known as wild soursop, this plant has anticancer effects, particularly in liver cancer, by enhancing liver function and regulating tumor suppressor gene expression [38]. It contains bioactive compounds such as alkaloids, glycosides, and flavonoids, which contribute to its therapeutic properties [39].

- ***Annona muricata***

*Annona muricata*, widely cultivated in Africa, has been shown to possess significant anticancer properties. Its acetogenins, particularly annonacin, have antitumor activities through apoptosis induction and cell cycle arrest [40,41]. Ethyl acetate extracts from its leaves have been effective against breast cancer cells [42]. The plant's silver nanoparticles (AgNPs) also exhibit anticancer effects by inducing autophagy and apoptosis [43].

- ***Aerva javanica***

*Aerva javanica*, native to Africa, has shown anticancer activity in breast cancer models. Methanol extracts from its callus and leaves induce DNA fragmentation and cytotoxicity in cancer cells [44,45].

- ***Azanza garckeana***

*Azanza garckeana*, a semi-deciduous tree from the Malvaceae family, is native to East and Southern Africa. Phytochemical analysis of its seeds reveals the presence of compounds such as tannins, saponins, flavonoids, alkaloids, phenols, glycosides, and carotenoids [46]. Flavonoids, integral to the plant's antioxidant properties, help neutralize free radicals, inhibiting tumor development. The seeds have been noted for their potential in reducing cancer development by interfering with the enzyme oestrogen synthase, responsible for producing estrogen [47]. Furthermore, a complex formed between Mansone G and  $\beta$ -Cyclodextrin, extracted from *A. garckeana*, has shown significant cytotoxic effects against A549 lung cancer cells [48].

- ***Phyllanthus amarus* (Euphorbiaceae)**

*Phyllanthus amarus* is a widely distributed herb across tropical regions, including Africa, Asia, and the Americas. The plant's extracts are known for their anticancer properties, particularly in initiating apoptosis in cancer cells. Research shows that *P. amarus* can induce cell cycle arrest in the G0/G1-phase and S-phase of different cancer cell lines, including PC-3 and MeWo, and hinder their migration, invasion, and adhesion [49]. In addition to its anticancer effects, *P. amarus* contains various phytochemicals such as flavonoids, ellagitannins, triterpenes, and alkaloids, which have been linked to its anticancer properties [44]. Studies have also highlighted its role in treating conditions like tubercular ulcers, wounds, and scabies, underlining its broad medicinal value.

- ***Thymus vulgaris* (Lamiaceae)**

*Thymus vulgaris*, commonly known as thyme, is a plant native to Southern Europe, the Mediterranean, and parts of Africa and Asia. The cytotoxic activity of extracts from *T. vulgaris* has been demonstrated in various cancer cell lines, including human breast cancer MCF-7 cells [41]. Active compounds like diallyl disulfide, diallyl trisulfide, and allicin have also shown strong anticancer potential, particularly in suppressing cancer cell proliferation [43]. These bioactive compounds make *T. vulgaris* a promising candidate for the development of natural anticancer agents.

- ***Spondias mombin***

This tropical plant possesses a diverse range of phytochemicals that contribute to its anticancer activity. Carotenoids from *S. mombin* promote cancer cell death and suppress tumor growth, particularly in breast cancer. Quercetin, a key flavonoid, triggers apoptosis, inhibits Bcl-2 proteins, suppresses NF- $\kappa$ B activation, and modulates PI3K/Akt and MAPK pathways. Kaempferol reduces angiogenesis by lowering VEGF levels and blocking Akt activation. Additionally, antioxidants like astaxanthin and  $\beta$ -carotene derivatives help reduce oxidative stress and DNA damage [50–55].

- ***Xanthosoma sagittifolium***

Known as tannia or malanga, this plant exhibits anticancer effects through induction of apoptosis, cell cycle arrest, and inhibition of angiogenesis. Its hydroethanolic extract is cytotoxic to leukemia cells, modulates NF- $\kappa$ B and STAT3 signaling, and acts through PTEN-related pathways [56–60].

- ***Elaeis guineensis***

Commonly referred to as oil palm, it contains tocotrienols and phenolic compounds with strong anticancer activity. Its methanol extract induces apoptosis and reduces cancer cell viability. Tocotrienols also arrest the cell cycle at G1 phase and inhibit key signaling pathways like NF- $\kappa$ B and MAPK [61–65].

- ***Irvingia gabonensis***

Also known as African mango, its bioactive components such as gallotannins, flavonoids, and terpenoids provide antioxidant, pro-apoptotic, and anti-inflammatory effects. The extracts activate mitochondrial apoptosis pathways and inhibit protein tyrosine phosphatases, helping regulate metabolism and immune responses [66,67].

- ***Blighia sapida***

Ackee contains saponins, alkaloids, and flavonoids that suppress ERK5—a pathway involved in breast cancer. It also displays antioxidant and anti-inflammatory properties, and promotes apoptosis in vitro [68–72].

- ***Talinum triangulare***

Waterleaf contains compounds like quercetin, apigenin, and lycopene that inhibit cancer cell growth and heat shock protein activity. It enhances immune response, reduces oxidative stress, and interferes with lipid peroxidation [73–78].

- *Launaea taraxacifolia*

African lettuce exhibits strong antioxidant activity due to its phenolics and flavonoids. It induces cell cycle arrest and apoptosis, notably in esophageal cancer cells [79–82].

- *Solanum macrocarpon*

African eggplant shows cytotoxicity against MCF-7 and HeLa cells. Glycoalkaloids like solamargine, along with flavonoids and phenolics, contribute to its antioxidant and immunomodulatory anticancer properties [83–88].

- *Chrysophyllum albidum*

African star apple is rich in phenolics and flavonoids, particularly in its leaf and fruit extracts. These compounds scavenge free radicals, induce apoptosis, and downregulate VEGF, which inhibits angiogenesis. Its extract has shown cytotoxic effects against breast cancer cells (MCF-7), suggesting potential as an antiangiogenic agent [89–91].

---

### Common Bioactive Compounds From African Medicinal Plants and Their Anticancer Mechanism

**Alkaloids:** Over recent years, several plant-based alkaloids have demonstrated cytotoxicity against various cancer cell lines. Proto-alkaloids differ from typical alkaloids in that their nitrogen atom originates from amino acid residues but is not part of a heterocyclic ring. Colchicine, a well-known proto-alkaloid from *Colchicum* species, has traditionally been used for inflammation [92]. Beyond this, it has shown anticancer properties: inducing apoptosis in breast cancer cells through p53, Bax, and caspase activation [93], suppressing  $\beta$ -catenin signaling in colon cancer cells [94], and promoting cell death in oral cancer via increased cytosolic calcium triggered by phospholipase C [95].

Neopapillarine, a coumarin-alkaloid conjugate found in *Neocryptodiscus papillaris*, exhibited selective cytotoxicity against renal cancer cell lines, although further studies are needed to elucidate its mechanism [96].

Indole alkaloids such as vinblastine and vincristine, used clinically in cancer therapy. New indole alkaloids like reflexin A from *Rauvolfia reflexa* have been shown to induce apoptosis via caspase pathways in colon cancer cells [97]. Acetoxystyberosine from *Alstonia yunnanensis* caused G1 phase arrest and apoptosis in liver cancer cells [98]. Chaetocochin J from *Chaetomium globosum* inhibited colorectal cancer cell growth via AMPK activation and autophagy induction. Caulerpin, extracted from *Halimeda cylindracea*, reduced migration and promoted apoptosis in lung and colon cancer cells with minimal toxicity to normal fibroblasts [99,100]. Another indole derivative, 3,10-dibromofascaplysin from *Fascaplysinopsis reticulata*, suppressed proliferation in drug-resistant prostate cancer cells by weakening androgen receptor activity [101].

Quinoline-based structures serve as scaffolds for various anticancer agents [102]. Alkaloids such as coclaurine and related benzyloquinolines from *Annona squamosa* inhibited growth in colon, breast, and liver cancer cells, with coclaurine showing superior potency due to more hydroxyl groups [103]. Neferine from *Nelumbo nucifera* triggered ROS generation and apoptosis in cervical cancer cells [104]. Other isoquinolines like palmatine and 6-methoxydihydroavicine disrupted glycolysis and mitochondrial functions in various cancers [105,106], while crebanine N-oxide from *Stephania hainanensis* caused G2/M arrest and apoptosis [107]. Camptothecin, a pyrroloquinoline alkaloid from *Camptotheca acuminata*, inhibits topoisomerase I, disrupting DNA replication and inducing cell death [108]. Its derivative, 10-hydroxycamptothecin, isolated from *Xylaria* fungi, inhibits BDR4 in triple-negative breast cancer cells [109].

**Flavonoids:** Flavonoids, a group of polyphenolic compounds abundantly present in plants, have gained considerable attention for their anticancer potential due to their natural origin, low toxicity, and multi-targeted action. Unlike conventional chemotherapeutic agents which often have significant side effects and limited selectivity, flavonoids exhibit cancer-preventive and therapeutic properties by interfering with carcinogenic processes such as cell proliferation, angiogenesis, apoptosis evasion, and metastasis [110–113]. For instance, quercetin a dietary flavonoid found in berries and green tea has been extensively studied for colorectal cancer, where it promotes apoptosis, cell cycle arrest, and modulates estrogen receptors and oxidative stress pathways [114]. Similarly, luteolin and kaempferol demonstrate pro-apoptotic activity in hepatocellular carcinoma by targeting specific molecular regulators like miR-6809-5p and oxidative stress pathways [115,116].

Recent investigations have highlighted various flavonoids with notable anticancer mechanisms. Hesperidin-loaded nanoparticles have shown cytotoxic effects against glioma cells with reduced polymer toxicity [117,118], while aurones and their analogues target a range of cellular proteins including kinases and histone deacetylases [119]. Myricetin, another bioactive flavonoid, exerts antimitotic effects in liver cancer cells by disrupting mitochondrial metabolism [120]. Several plant extracts rich in flavonoids, such as those from *Matricaria recutita* and *Gastrocotyle hispida*, demonstrate dose-dependent cytotoxicity against hepatocellular and other cancer cell lines by modulating VEGF expression and other critical molecular targets [121,122]. Prenylated flavonoids, including those from *Sinopodophyllum hexandrum*, show potent cytotoxic activity with IC<sub>50</sub> values under 10  $\mu$ mol/L, indicating strong anticancer efficacy [123].

While many of these compounds remain in preclinical evaluation, a few have entered advanced clinical trials. Notably, icaritin (ICT), a prenylated flavonoid, is in phase III trials for hepatocellular carcinoma, showing immune-enhancing properties and targeting key pathways like STAT3 and NF $\kappa$ B [124]. Isoquercetin has also progressed to clinical trials for reducing thrombosis in cancer patients by inhibiting protein disulfide isomerase activity [125].

These studies underscore the therapeutic potential of flavonoids as safer, plant-based anticancer agents. Given my interest in drug discovery and plant natural products, the integration of such bioactive compounds into modern oncology could lead to innovative and less toxic treatment strategies.

**Terpenoids and Triterpenes:** Terpenoids, a diverse and structurally rich class of natural compounds primarily found in medicinal plants, have shown immense promise in cancer therapy. Their biosynthesis, derived from isoprene units, contributes to a wide range of bioactive molecules that exert cytotoxic effects on various cancer cell lines. These compounds function through mechanisms such as inducing apoptosis, inhibiting angiogenesis, and suppressing metastasis, making them attractive candidates for anticancer drug development. Notably, diterpenoids like taxol and triterpenoids such as ursolic acid have been extensively studied and utilized in chemotherapeutic formulations [126,127].

The anticancer effects of terpenoids are mediated through multiple molecular targets and pathways, including modulation of oxidative stress, interference with the cell cycle, and inhibition of pro-survival signaling cascades like PI3K/Akt and NF- $\kappa$ B. For instance, monoterpenes such as limonene and perillyl alcohol have demonstrated significant efficacy in both in vitro and clinical settings, showing their ability to sensitize tumor cells to conventional therapies (128). Moreover, some sesquiterpenes have shown potential in overcoming multidrug resistance, a major hurdle in cancer treatment, by altering membrane permeability and drug efflux pump expression (129).

Recent research continues to highlight the therapeutic relevance of plant-derived terpenoids in oncology, reinforcing their role not just as cytotoxic agents but also as chemopreventive molecules. With a strong basis in traditional medicine and modern pharmacological validation, these natural compounds are being explored for formulation into novel drug delivery systems to enhance bioavailability and selectivity. This aligns with the growing scientific interest in integrating ethnopharmacological knowledge with molecular oncology to develop safer, plant-based anticancer therapeutics (130, 131).

**Tannin:** Tannins, a class of polyphenolic compounds found abundantly in many medicinal plants, have exhibited notable cytotoxic and antiproliferative activities against cancer cells. In particular, aqueous leaf extracts from various *Cornus* species such as *C. mas*, *C. alba*, and *C. officinalis* demonstrated strong inhibitory effects on MCF-7 breast cancer cells, with survival rates dropping to nearly 11% after 72 hours of treatment. These effects correlated closely with high tannin content, although other polyphenols such as flavonoids and hydroxycinnamic derivatives also contributed modestly to cytotoxicity [132, 133]. Similarly, extracts from *Crateva adansonii*, an African ethnomedicinal plant, significantly reduced tumour volume and oxidative stress in a rat breast cancer model, largely attributed to its gallotannin and flavonoid content [134].

Further evidence of tannins' anticancer potential comes from *Caesalpinia spinosa* (P2Et), a Peruvian medicinal plant rich in gallotannins. Its ethanolic extract induced apoptosis in breast tumour cells and triggered immunogenic cell death (ICD) markers like calreticulin and ATP release [135, 136]. These immunomodulatory effects enhanced anti-tumour immunity, as seen in the increased activation of CD4+ and CD8+ T cells. Moreover, this extract reduced lung and spleen metastases in vivo and demonstrated a synergistic effect with doxorubicin in combating cancer stem cells (CSC) in resistant breast cancer models [137–139]. These findings support the integration of tannin-rich plant extracts as potent adjuvants in cancer therapy, particularly for resistant and metastatic cancers.

**Quinones:** Quinones, a diverse class of natural compounds found in many medicinal plants, exhibit significant anticancer potential by targeting multiple pathways involved in tumor progression. Compounds like aloe-emodin have been shown to disrupt cancer cell proliferation by arresting the cell cycle at various checkpoints including G1, S, and G2/M phases [140–141]. These bioactive molecules also induce oxidative stress by generating reactive oxygen species (ROS), which in turn cause DNA damage [145]. Additionally, quinones can activate intrinsic and extrinsic apoptotic mechanisms through the modulation of caspases, the Fas signaling pathway, the tumor suppressor protein p53, and c-Jun N-terminal kinase, ultimately promoting programmed cancer cell death [140, 144, 146, 147].

Beyond inducing apoptosis, quinones exert their anticancer effects by suppressing metastasis-related proteins and signaling pathways. They have been found to inhibit the expression of urokinase-type plasminogen activator as well as matrix metalloproteinases MMP-2 and MMP-9, which are critical for tumor invasion and metastasis [150, 151, 152]. One notable quinone,  $\beta$ -lapachone, has been reported to cause DNA fragmentation and apoptotic body formation, while downregulating anti-apoptotic proteins like Bcl-2 and Bcl-XL. It simultaneously enhances the expression of pro-apoptotic protein Bax and activates poly (ADP-ribose) polymerase along with caspases-3 and -9, further reinforcing its potential as a promising anticancer agent [153]. These findings underscore the therapeutic relevance of quinones in the development of plant-based anticancer drugs.

---

## Conclusion

Traditional African medicinal plants possess vast potential as sources of anticancer agents due to their diverse bioactive compounds and long-standing use in indigenous healthcare systems. This review underscores the therapeutic promise of these plants in combating various cancers through mechanisms such as apoptosis induction, anti-proliferation, and metastasis inhibition. While numerous in vitro and in vivo studies have demonstrated promising results, challenges remain in terms of clinical validation, toxicity profiling, and standardization. Bridging the gap between traditional knowledge and modern scientific research is essential for harnessing the full therapeutic potential of African botanicals.

---

## Future Directions

- **Phytochemical Standardization:** Development of standardized extraction and formulation protocols to ensure consistency in bioactive content.
- **Mechanistic Studies:** Advanced molecular studies to elucidate precise mechanisms of action of plant-derived compounds.

- Preclinical and Clinical Trials: Comprehensive in vivo studies followed by human clinical trials to validate safety and efficacy.
- Bioprospecting and Conservation: Sustainable harvesting and conservation strategies to protect biodiversity while exploring novel anticancer compounds.
- Ethnopharmacological Integration: Strengthening collaboration between traditional healers and scientific researchers to validate and preserve indigenous knowledge.

### Acknowledgment

The authors acknowledge the invaluable contributions of traditional healers and herbal practitioners across Africa whose indigenous knowledge laid the foundation for this review. We also extend our gratitude to our academic institutions and research collaborators for their support. Special thanks to the libraries that provided access to relevant scientific literature and databases.

### References

1. WHO (2020). *Global Health Estimates: Life expectancy and leading causes of death and disability*. World Health Organization.
2. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, **71**(2), 209–249.
3. Bray, F., Laversanne, M., Weiderpass, E., & Soerjomataram, I. (2021). The ever-increasing importance of cancer as a leading cause of premature death worldwide. *Cancer*, **127**(17), 3029–3030.
4. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, **71**(2), 209–249.
5. Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013). Exploiting nanotechnology to overcome tumor drug resistance: challenges and opportunities. *Advanced Drug Delivery Reviews*, **65**(13), 1731–1747.
6. Yi, X., Yang, K., Liang, C., Zhong, X., Ning, P., Song, G., Wang, D., Ge, C., Chen, C., Chai, Z., & Liu, Z. (2015). Imaging-guided combined photothermal and radiotherapy to treat subcutaneous and metastatic tumors using Iodine-131-doped copper sulfide nanoparticles. *Advanced Functional Materials*, **25**(30), 4689–4699.
7. Couliadiati, T. H. (2019). Burden of cancer and role of traditional medicine in Burkina Faso. *IJCAM*, **12**, 194–200.
8. Nwodo, J. N., Ibezim, A., Simoben, C. V., & Ntie-Kang, F. (2016). Exploring cancer therapeutics with natural products from African medicinal plants, part II: alkaloids, terpenoids and flavonoids. *Anti-Cancer Agents in Medicinal Chemistry*, **16**(1), 108–127.
9. Wang, J. J., Lei, K. F., & Han, F. (2018). Tumor microenvironment: recent advances in various cancer treatments. *European Review for Medical and Pharmacological Sciences*, **22**(12), 3855–3864.
10. Noble, R. L. (1990). The discovery of the vinca alkaloids chemotherapeutic agents against cancer. *Biochemistry and Cell Biology*, **68**(12), 1344–1351.
11. Keglevich, P., Hazai, L., Kalaus, G., & Szántay, C. (2012). Modifications on the basic skeletons of vinblastine and vincristine. *Molecules*, **17**(5), 5893–5914.
12. El-Seedi, H. R., Burman, R., Mansour, A., Turki, Z., Boulos, L., Gullbo, J., et al. (2013). The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: Discovery of an active cardiac glycoside from *Urginea maritima*. *Journal of Ethnopharmacology*, **145**(3), 746–757.
13. Adeoye, B. O., Iyanda, A. A., Daniyan, M. O., Adeoye, A. D., Oyerinde, A. M., & Olatinwo, G. O. (2022). Botanical and bioactive markers of Nigerian bitter honey. *Tropical Journal of Natural Product Research*, **6**(11), 1848–1853.
14. Xie, S., & Zhou, J. (2017). Harnessing plant biodiversity for the discovery of novel anticancer drugs targeting microtubules. *Frontiers in Plant Science*, **8**, 720.
15. Boadu, A., Karpoormath, R., & Nlooto, M. (2024). *Spondias mombin*: biosafety and GC-MS analysis of anti-viral compounds from crude leaf extracts. *Advances in Traditional Medicine*, **24**(1), 349–372.
16. Sawadogo, W. R., Schumacher, M., Teiten, M.-H., Dicato, M., & Diederich, M. (2012). Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. *Biochemical Pharmacology*, **84**(10), 1225–1240.
17. Amin, A., Gali-Muhtasib, H., Ocker, M., & Schneider-Stock, R. (2009). Overview of major classes of plant-derived anticancer drugs. *International Journal of Biomedical Science*, **5**(1), 1–11.

18. Kluska, M., & Woźniak, K. (2021). Natural polyphenols as modulators of etoposide anti-cancer activity. *International Journal of Molecular Sciences*, **22**(12), 6602.
19. Hwang, J. T., Kwak, D. W., Lin, S. K., Kim, H. M., Kim, Y. M., & Park, O. J. (2007). Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. *Annals of the New York Academy of Sciences*, **1095**(1), 441–448.
20. Balogun, F., & Ashafa, A. (2017). Aqueous root extracts of *Dicoma anomala* (Sond.) extenuates postprandial hyperglycaemia in vitro and its modulation on the activities of carbohydrate-metabolizing enzymes in streptozotocin-induced diabetic Wistar rats. *South African Journal of Botany*, **112**, 102–111.
21. Shafiq A., Moore J., Suleman A., Faiz S., Farooq O., Arshad A., et al. (2020). Elevated soluble galectin-3 as a marker of chemotherapy efficacy in breast cancer patients: A prospective study. *Int. J. Breast Cancer*, **2020**, (0), 4824813.
22. Asita A. O., Heisi D. H., Tjale T. (2015). Modulation of mutagen-induced genotoxicity by two Lesotho medicinal plants in *Allium cepa* L. *Environ. Nat. Resour. Res.*, **5**, (3), 37.
23. Yiaile A. L. (2017). “vitro antiploriferative activity,” in Phytochemical composition and toxicity studies of *Fagaropsis angolensis* and *Prunus africana* crude extracts (University of Nairobi; ).
24. Misonge O. J., Kamindu G. N., Sabina W., Muita G. (2019). An ethnobotanical survey of plants used for the treatment and management of cancer in Embu County, Kenya. *J. Med. Plants*, **7**, (0), 39–46.
25. Onyancha J. M., Gikonyo N. K., Wachira S. W., Mwitari P. G., Gicheru M. M. (2018). Anticancer activities and safety evaluation of selected Kenyan plant extracts against breast cancer cell lines. *J. Pharmacogn. Phytotherapy*, **10**, (0), 21–26.
26. Yang Z., Garcia A., Xu S., Powell D. R., Vertino P. M., Singh S., et al. (2013). *Withania somnifera* root extract inhibits mammary cancer metastasis and epithelial to mesenchymal transition. *PLoS One*, **8**, (0), e75069.
27. Shikder M., Al Hasib T., Kabir M. L. (2020). Anticancer mechanism of *Withania somnifera* and its bioactive compounds: A short review along with computational molecular docking study.
28. Vamsi K. B., Glory T. J., Florida T., Aneesh N., Rekha L., Thangaraj P. (2020). Gene expression analysis of EGFR and PI3K genes in A549 lung cancer cell line treated with *Withania somnifera* root extract. *Res. J. Biotechnol.*, **15**, (0), 2.
29. Senthilnathan P., Padmavathi R., Banu S. M., Sakthisekaran D. (2006a). Enhancement of antitumor effect of paclitaxel in combination with immunomodulatory *Withania somnifera* on benzo (a) pyrene induced experimental lung cancer. *Chemico-biological Interact.*, **159**, (0), 180–185.
30. Grace O., Prendergast H., Jäger A., Van Staden J., Van Wyk A. (2003). Bark medicines used in traditional healthcare in KwaZulu-Natal, South Africa: An inventory. *South Afr. J. Bot.*, **69**, (0), 301–363.
31. Ochwang'i D. O., Kimwele C. N., Oduma J. A., Gathumbi P. K., Mbaria J. M., Kiama S. G. (2014). Medicinal plants used in treatment and management of cancer in Kakamega County, Kenya. *J. Ethnopharmacol.*, **151**, (0), 1040–1055.
32. Komakech R., Kang Y. (2019). Ethnopharmacological potential of African cherry [*Prunus africana*]. *J. Herb. Med.*, **17**, (0), 100283.
33. Komakech R., Yim N.-H., Shim K.-S., Jung H., Byun J.-E., Lee J., et al. (2022). Root extract of a micropropagated *Prunus africana* medicinal plant induced apoptosis in human prostate cancer cells (PC-3) via caspase-3 activation. *Evidence-Based Complementary Altern. Med.*, **2022**, (0), 8232851.
34. Saidu I. N., Umar K. S., Isa M. H. (2015). Ethnobotanical survey of anticancer plants in Askira/Uba local government area of Borno State, Nigeria. *Afr. J. Pharm. Pharmacol.*, **9**, (0), 123–130.
35. Ngulde S. I., Sandabe U. K., Abounader R., Dawson T. K., Zhang Y., Iliya I., et al. (2019). Ethanol extract of *Securidaca longipedunculata* induces apoptosis in brain tumor (U87) cells. *BioMed Res. Int.*, **2019**, (0), 9826590.
36. Mitaine-Offer A.-C., Pérez N., Miyamoto T., Delaude C., Mirjolet J.-F., Duchamp O., et al. (2010). Acylated triterpene saponins from the roots of *Securidaca longipedunculata*. *Phytochemistry*, **71**, (0), 90–94.
37. Zuo J., Jiang H., Zhu Y.-H., Wang Y.-Q., Zhang W., Luan J.-J. (2016). Regulation of MAPKs signaling contributes to the growth inhibition of 1, 7-dihydroxy-3, 4-dimethoxyxanthone on multidrug resistance A549/taxol cells. *Evidence-Based Complementary Altern. Med.*, **2016**, (0), 2018704.
38. Yakubu O. F., Metibemu D. S., Adelani I. B., Adesina G. O., Edokwe C. B., Oseha O. E., et al. (2020). *Annona senegalensis* extract demonstrates anticancer properties in N-diethylnitrosamine-induced hepatocellular carcinoma in male Wistar rats. *Biomed. Pharmacother.*, **131**, (0), 110786.

39. Potchoo Y., Richard D., Sakie E., Guissou I., Kini F., Yaro B. (2008). Comparative phytochemical content of leaves extracts of two *Annona senegalensis* Pers: The one from Togo and the other originates from Burkina Faso. *J. Biol. Sci.*, **8**, (0), 577–583.
40. Fang X. P., Rieser M. J., Gu Z. M., Zhao G. X., McLaughlin J. L. (1993). Annonaceous acetogenins: An updated review. *Phytochem. Anal.*, **4**, (0), 27–48.
41. Yap C. V., Subramaniam K. S., Khor S. W., & Chung I. (2017). Annonacin exerts antitumor activity through induction of apoptosis and extracellular signal-regulated kinase inhibition. *Pharmacogn. Res.*, **9**(–), 378–383.
42. Jabir M. S., Saleh Y. M., Sulaiman G. M., Yaseen N. Y., Sahib U. I., Dewir Y. H., et al. (2021). Green synthesis of silver nanoparticles using *Annona muricata* extract as an inducer of apoptosis in cancer cells and inhibitor for NLRP3 inflammasome via enhanced autophagy. *Nanomaterials*, **11**(–), 384.
43. Eritja N., Chen B.-J., Rodríguez-Barrueco R., Santacana M., Gatiús S., Vidal A., et al. (2017). Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. *Autophagy*, **13**(–), 608–624.
44. Teklehaymanot T. (2009). Ethnobotanical study of knowledge and medicinal plants use by the people in Dek Island in Ethiopia. *J. Ethnopharmacol.*, **124**(–), 69–78.
45. Abate L., Tadesse M. G., Bachheti A., & Bachheti R. K. (2022). Traditional and phytochemical bases of herbs, shrubs, climbers, and trees from Ethiopia for their anticancer response. *BioMed Res. Int.*, **2022**(–), 1589877.
46. Michael K., Onyia L., & Jidauna S. (2015). Evaluation of phytochemicals in *Azanza garckeana* (Gorontula) seed. *J. Agric. Veterinary Sci.*, **8**(–), 71–74.
47. Okwu D. (2005). Phytochemicals, vitamins and mineral contents of two Nigerian medicinal plants. *Int. J. Mol. Med. Adv. Sci.*, **1**(–), 375–381.
48. Bioltif Y. E., Edward N. B., & Tyeng T. D. (2020). A chemical overview of *Azanza garckeana*. *Biol. Med. Nat. Prod. Chem.*, **9**(–), 91–95.
49. Ngulde S. I., Sandabe U. K., Abounader R., Dawson T. K., Zhang Y., Iliya I., et al. (2019). Ethanol extract of *Securidaca longipedunculata* induces apoptosis in brain tumor (U87) cells. *BioMed Res. Int.*, **2019**(–), 9826590.
50. Boadu A., Karpoomath R., & Nlooto M. *Spondias mombin*: biosafety and GC-MS analysis of anti-viral compounds from crude leaf extracts. *Adv Tradit Med*, **24**(1), 349–372.
51. Metibemu D. S., Akinloye O. A., Akamo A. J., Okoye J. O., Ojo D. A., Morifi E., et al. Carotenoid isolates of *Spondias mombin* demonstrate anticancer effects in DMBA-induced breast cancer in Wistar rats through X-linked inhibitor of apoptosis protein (XIAP) antagonism and anti-inflammation. *J Food Biochem*, **44**(12), e13523.
52. Primikyri A., Chatziathanasiadou M. V., Karali E., Kostaras E., Mantzaris M. D., Hatzimichael E., et al. Direct binding of Bcl-2 family proteins by quercetin triggers its pro-apoptotic activity. *ACS Chem Biol*, **9**(12), 2737–2741.
53. Chin H. K., Horng C. T., Liu Y. S., Lu C. C., Su C. Y., Chen P. S., et al. Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT, MEK and ERK pathways in VEGF-stimulated human umbilical vein endothelial cells. *Oncol Rep*, **39**(5), 2351–2357.
54. Nworu C. S., Akah P. A., Okoye F. B., Toukam D. K., Udeh J., & Esimone C. O. The leaf extract of *Spondias mombin* L. displays an anti-inflammatory effect and suppresses inducible formation of tumor necrosis factor- $\alpha$  and nitric oxide (NO). *J Immunotoxicol*, **8**(1), 10–16.
55. Osuntokun O. T. Exploring the Medicinal Efficacy, Properties and Therapeutic uses of *Spondias mombin* (Linn). *Int J Appl Res Med Plants*, **2**(1), 115.
56. Graf B. L., Zhang L., Corradini M. G., Kuhn P., Newman S. S., Salbaum J. M., et al. Physicochemical differences between malanga (*Xanthosoma sagittifolium*) and potato (*Solanum tuberosum*) tubers are associated with differential effects on the gut microbiome. *J Funct Foods*, **45**(–), 268–276.
57. Caxito M. L., Correia R. R., Gomes A. C., Justo G., Coelho M. G., Sakuragui C. M., et al. In Vitro Antileukemic Activity of *Xanthosoma sagittifolium* (Taioba) Leaf Extract. *Evid Based Complement Alternat Med*, **2015**(–), 384267.
58. Fulton A., & Kundu N. University of Maryland, Baltimore, assignee. Natural plant products for control of cancer metastasis. World Patent WO 2011/115651 A2. 2011 September 22.
59. Arruda S. F., Siqueira E. M., & Souza E. M. *Malanga* (*Xanthosoma sagittifolium*) and purslane (*Portulaca oleracea*) leaves reduce oxidative stress in vitamin A-deficient rats. *Ann Nutr Metab*, **48**(4), 288–295.
60. de Almeida Jackix E., Monteiro E. B., Raposo H. F., Vanzela E. C., & Amaya-Farfán J. *Taioba* (*Xanthosoma sagittifolium*) leaves: nutrient composition and physiological effects on healthy rats. *J Food Sci*, **78**(12), H1929–H1934.

61. Adeoye OB., Iyanda AA., Daniyan MO., Adeoye DA., Olajide OL., Akinnawo OO., **et al.** (2023). Anti-dyslipidaemia and cardio-protective effects of Nigerian bitter honey in streptozotocin induced diabetic rats. *Universal Journal of Pharmaceutical Research*, **8**(2):10–18.
62. Vijayarathna S., & Sasidharan S. (2012). Cytotoxicity of methanol extracts of *Elaeis guineensis* on MCF-7 and Vero cell lines. *Asian Pacific Journal of Tropical Biomedicine*, **2**(10):826–829.
63. Owoyele BV., & Owolabi GO. (2014). Traditional oil palm (*Elaeis guineensis* Jacq.) and its medicinal uses: A review. *TANG*, **4**(3):16.1–16.8.
64. Lubis HML., Purwoningsih E., Nasution AA., & Salim QM. (2022). Mechanism of action of tumorigenesis of anticancer molecules of palm oil tocotrienols (*Elaeis guineensis* Jacq.): A systematic review. *Eduvest - Journal of Universal Studies*, **2**(2):431–440.
65. Ji X., Usman A., Razalli NH., Sambanthamurthi R., & Gupta SV. (2015). Oil palm phenolics (OPP) inhibit pancreatic cancer cell proliferation via suppression of NF-κB pathway. *Anticancer Research*, **35**(1):97–106.
66. Olorundare O., Adeneye A., Akinsola A., Kolo P., Agede O., Soyemi S., **et al.** (2020). *Irvingia gabonensis* seed extract: An effective attenuator of doxorubicin-mediated cardiotoxicity in Wistar rats. *Oxidative Medicine and Cellular Longevity*, **2020**:1602816.
67. Yoon SY., Kim J., Lee BS., Baek SC., Chung SJ., & Kim KH. (2022). Terminalin from African mango (*Irvingia gabonensis*) stimulates glucose uptake through inhibition of protein tyrosine phosphatases. *Biomolecules*, **12**(2):321.
68. Dossou VM., Agbenorhevi JK., Combey S., & Afi-Koryoe S. (2014). Ackee (*Blighia sapida*) fruit arils: Nutritional, phytochemicals and antioxidant properties. *International Journal of Nutrition and Food Sciences*, **3**(6):534.
69. Bodun DS., Omoboyowa DA., Adedara JF., Olugbogi EA., Oluwamorofo FO., Atasie NH., **et al.** (2023). Virtual screening of flavonoids from *Blighia sapida* against ERK5 involved in breast cancer. *Proceedings of the Indian National Science Academy*, **89**:957–966.
70. Ibraheem O., Oyewole TA., Adedara A., Abolaji AO., Ogundipe OM., Akinyelu J., **et al.** (2022). Ackee (*Blighia sapida* K.D. Koenig) leaves and arils methanolic extracts ameliorate CdCl<sub>2</sub>-induced oxidative stress biomarkers in *Drosophila melanogaster*. *Oxidative Medicine and Cellular Longevity*, **2022**:3235031.
71. Belahcene S., Kebsa W., Omoboyowa DA., Alshihri AA., Alelyani M., Bakkour Y., **et al.** (2023). Unveiling the chemical profiling, antioxidant and anti-inflammatory activities of Algerian *Myrtus communis* L. essential oils, and exploring molecular docking to predict the inhibitory compounds against cyclooxygenase-2. *Pharmaceuticals (Basel)*, **16**(10):1343.
72. Sitarek P., Merecz-Sadowska A., Śliwiński T., Zajdel R., & Kowalczyk T. (2020). An in vitro evaluation of the molecular mechanisms of action of medical plants from the Lamiaceae family as effective sources of active compounds against human cancer cell lines. *Cancers (Basel)*, **12**(10):2957.
73. Barman D., Puro KN., Boruah JLH., Kumar D., Medhi K., Mazumder B., **et al.** (2024). *Talinum triangulare* (Jacq.) Willd: A review of its traditional uses, phytochemistry, and pharmacology along with network pharmacology analysis of its components and targets. *Food Chemistry Advances*, **5**:100768.
74. Liao DY., Chai YC., Wang SH., Chen CW., & Tsai MS. (2015). Antioxidant activities and contents of flavonoids and phenolic acids of *Talinum triangulare* extracts and their immunomodulatory effects. *Journal of Food and Drug Analysis*, **23**(2):294–302.
75. Dinesh A., & Kumar A. (2023). A review on bioactive compounds, ethnomedicinal importance and pharmacological activities of *Talinum triangulare* (Jacq.) Willd. *Chemistry & Biodiversity*, **20**(12):e202301079.
76. Chen X., Dong XS., Gao HY., Jiang YF., Jin YL., Chang YY., **et al.** (2016). Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells. *Molecular Medicine Reports*, **13**(1):689–696.
77. Afolabi OB., Oloyede OI., Jaiyesimi KF., Obafemi TO., Awe JO., & Fadaka AO. (2015). Antagonistic potentials of *Talinum triangulare* extracts against iron II-induced oxidative stress in tissue homogenates of Wistar albino rat – in vitro. *World Journal of Pharmacy and Pharmaceutical Sciences*, **4**(6):59–67.
78. Oladele OT., Oladele JO., Ajayi EIO., Alabi KE., Oyeleke OM., Atolagbe OS., **et al.** (2024). Bioactive composition and protective properties of *Talinum triangulare* in dextran sodium sulphate-induced ulcerative colitis in rats. *Pharmacological Research - Modern Chinese Medicine*, **10**:100344.
79. Thomford NE., Mkhize B., Dzobo K., Mpye K., Rowe A., Parker MI., **et al.** (2016). African lettuce (*Launaea taraxacifolia*) displays possible anticancer effects and herb-drug interaction potential by CYP1A2, CYP2C9, and CYP2C19 inhibition. *OMICS*, **20**(9):528–537.
80. Adinortey MB., Ansah C., Weremfo A., Adinortey CA., Adukpo GE., Ameyaw EO., **et al.** (2018). DNA damage protecting activity and antioxidant potential of *Launaea taraxacifolia* leaves extract. *Journal of Natural Science, Biology and Medicine*, **9**(1):6–13.
81. Adinortey MB., Sarfo JK., Kwarteng J., Adinortey CA., Ekloho W., Kuatsienue LE, **et al.** (2018). The Ethnopharmacological and Nutraceutical Relevance of *Launaea taraxacifolia* (Willd.) Amin ex C. Jeffrey. *Evid Based Complement Alternat Med*, **2018**(7259146):1-10.

82. Koukoui O, Agbangnan P, Boucherie S, Yovo M, Nusse O, Combettes L, et al. (2015). Phytochemical Study and Evaluation of Cytotoxicity, Antioxidant and Hypolipidemic Properties of *Launaea taraxacifolia* Leaves Extracts on Cell Lines HepG2 and PLB985. *Am J Plant Sci*, **6**(11):1768-1779.
83. Mansurat AI, Dandago MA, Diya'udeen HB. (2023). Phytochemical Contents and Antioxidant potentials of Eggplants from Kano State, Nigeria: A Review. *Dutse J Pure Appl Sci*, **9**(1a):160-167.
84. Sun J, Hai Liu R. (2006). Cranberry phytochemical extracts induce cell cycle arrest and apoptosis in human MCF-7 breast cancer cells. *Cancer Lett*, **241**(1):124-134.
85. Osei-Owusu J, Kokro KB, Ofori A, Apau J, Dofuor AK, Vigbedor BY, et al. (2023). Evaluation of phytochemical, proximate, antioxidant, and anti-nutrient properties of *Corchorus olitorius*, *Solanum macrocarpon* and *Amaranthus cruentus* in Ghana. *Int J Biochem Mol Biol*, **14**(2):17-24.
86. Oluremi BB, Oloche JJ, Adeniji AJ. (2021). Anticancer and Antibacterial Activities of *Solanum aethiopicum* L., *Solanum macrocarpon* L. and *Garcinia kola* Heckel. *Trop J Nat Prod Res*, **5**(5):938-942.
87. Chinedu SN, Olasumbo AC, Eboji OK, Emiloju OC, Arinola OK, Dania DI. (2011). Proximate and Phytochemical Analyses of *Solanum aethiopicum* L. and *Solanum macrocarpon* L. Fruits. *Res J Chem Sci*, **1**(3):63-71.
88. Eletta OAA, Orimolade BO, Oluwaniyi OO, Dosumu OO. (2017). Evaluation of proximate and antioxidant activities of Ethiopian eggplant (*Solanum aethiopicum* L) and Gboma Eggplant (*Solanum macrocarpon* L). *J Appl Sci Environ Manag*, **21**(5):967-972.
89. Akinmoladun AC, Falaiye OE, Ojo OB, Adeoti A, Amoo ZA, Olaleye MT. (2022). Effect of extraction technique, solvent polarity, and plant matrix on the antioxidant properties of *Chrysophyllum albidum* G. Don (African Star Apple). *Bull Natl Res Cent*, **46**(1):40.
90. Oguntoyinbo OO, Abdus-salaam RB, Bello WA, Ifesan BOT. (2015). Evaluation of the Phytochemical, Antioxidant and Antimicrobial properties of Extracts from *Chrysophyllum Albidum* (African Star Apple) Leaf. *J Food Technol Res*, **2**(1):1-10.
91. Okoli BJ, Okere OS. (2010). Antimicrobial Activity of the Phytochemical Constituents of *Chrysophyllum Albidum* G.Don\_Holl. (African Star Apple) Plant. *J Res Natl Inst Stand Technol*, **8**(1):301-311.
92. Mbaveng, A.T., Noulala, C.G., Samba, A.R., Tankeo, S.B., Abdelfatah, S., Fotso, G.W., Happi, E.N., Ngadjui, B.T., Beng, V.P., Kuete, V. (2021). The alkaloid, soyauxinium chloride, displays remarkable cytotoxic effects towards a panel of cancer cells, inducing apoptosis, ferroptosis and necroptosis. *Chem. Biol. Interact.*, **333** (109334).
93. Becer, E., Hanoğlu, D.Y., Kabadayı, H., Hanoğlu, A., Vatansever, S., Yavuz, D.Ö., Meriçli, F., Meriçli, A.H. (2019). The effect of *Colchicum pusillum* in human colon cancer cells via Wnt/ $\beta$ -catenin pathway. *Gene*, **686** (213–219).
94. Hu, S., Yin, J., Yan, S., Hu, P., Huang, J., Zhang, G., Wang, F., Tong, Q., Zhang, Y. (2021). Chaetocochin J, an epipolythiodioxopiperazine alkaloid, induces apoptosis and autophagy in colorectal cancer via AMPK and PI3K/AKT/mTOR pathways. *Bioorg. Chem.*, **109** (104693).
95. Xu, G.B., He, G., Bai, H.H., Yang, T., Zhang, G.L., Wu, L.W., Li, G.Y. (2015). Indole alkaloids from *Chaetomium globosum*. *J. Nat. Prod.*, **78** (1479–1485).
96. Dasari, S., Bakthavachalam, V., Chinnapaka, S., Venkatesan, R., Samy, A.L., Munirathinam, G. (2020). Neferine, an alkaloid from *lotus* seed embryo targets HeLa and SiHa cervical cancer cells via pro-oxidant anticancer mechanism. *Phytother. Res.*, **34** (2366–2384).
97. Kumar, S., Agnihotri, N. (2019). Piperlongumine, a piper alkaloid targets Ras/PI3K/Akt/mTOR signaling axis to inhibit tumor cell growth and proliferation in DMH/DSS induced experimental colon cancer. *Biomed. Pharmacother.*, **109** (1462–1477).
98. Ma, N., Shangguan, F., Zhou, H., Huang, H., Lei, J., An, J., Jin, G., Zhuang, W., Zhou, S., Wu, S. (2022). 6-methoxydihydroavicine, the alkaloid extracted from *Macleaya cordata* (Willd.) R. Br. (Papaveraceae), triggers RIPK1/Caspase-dependent cell death in pancreatic cancer cells through the disruption of oxaloacetic acid metabolism and accumulation of reactive oxygen species. *Phytomedicine*, **102** (154164).
99. Si, P., Chen, H., Liu, J., Zhang, E., Li, C., Gu, J., Wang, R., Li, W. (2022). Identification of (S)-10-Hydroxycamptothecin as a potent BRD4 inhibitor for treating triple-negative breast cancer. *J. Mol. Struct.*, **1265** (133366).
100. Li, F., Jiang, T., Li, Q., Ling, X. (2017). Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: Did we miss something in CPT analogue molecular targets for treating human disease such as cancer? *Am. J. Cancer Res.*, **7** (2350).
101. Ito, C., Itoigawa, M., Sato, A., Hasan, C.M., Rashid, M.A., Tokuda, H., Mukainaka, T., Nishino, H., Furukawa, H. (2004). Chemical Constituents of *Glycosmis arborea*: Three New Carbazole Alkaloids and Their Biological Activity. *J. Nat. Prod.*, **67** (1488–1491).
102. Matada, B.S., Pattanashettar, R., Yernale, N.G. (2021). A comprehensive review on the biological interest of quinoline and its derivatives. *Bioorg. Med. Chem.*, **32** (115973).

103. Zhang, H., Shangguan, F., Zhang, L., Ma, N., Song, S., Ma, L., Liu, C., Liu, M., An, J., Li, H. (2023). A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/MAPK mediated apoptosis. *Front Pharmacol.*, **14** (1093650).
104. Still, P.C., Yi, B., González-Cestari, T.F., Pan, L., Pavlovicz, R.E., Chai, H.-B., Ninh, T.N., Li, C., Soejarto, D.D., McKay, D.B. (2013). Alkaloids from *Microcos paniculata* with cytotoxic and nicotinic receptor antagonistic activities. *J. Nat. Prod.*, **76** (243–249).
105. Zhidkov, M.E., Kaune, M., Kantemirov, A.V., Smirnova, P.A., Spirin, P.V., Sidorova, M.A., Stadnik, S.A., Shyrokov, E.Y., Kaluzhny, D.N., Tryapkin, O.A. (2022). Study of Structure–Activity Relationships of the Marine Alkaloid Fascaplysin and Its Derivatives as Potent Anticancer Agents. *Mar. Drugs*, **20** (185).
106. Tosun, F., Mıhoğlugil, F., Beutler, J.A., Eroğlu Özkan, E., Miski, M. (2020). Neopapillarine, an unusual coumarino-alkaloid from the root extract of *neocryptodiscus papillaris* with cytotoxic activity on renal cancer cells. *Molecules*, **25** (3040).
107. Sun, G.C., Chen, H.H., Liang, W.Z., Jan, C.R. (2019). Exploration of the effect of the alkaloid colchicine on Ca<sup>2+</sup> handling and its related physiology in human oral cancer cells. *Arch. Oral Biol.*, **102** (179–185).
108. Lai, Q., Yang, C.J., Zhuang, M., Ma, Y.H., Lin, C.Y., Zeng, G.Z., Yin, J.L. (2022). Alkaloid from *Alstonia yunnanensis* Diels root against gastrointestinal cancer: Acetoxystabermosine inhibits apoptosis in hepatocellular carcinoma cells. *Front. Pharmacol.*, **13**(1085309).
109. Al-Ghazzawi, A.M. (2019). Anti-cancer activity of new benzyl isoquinoline alkaloid from Saudi plant *Annona squamosa*. *BMC Chem.*, **13**(1–6).
110. Wagner, C.E., Jurutka, P.W., Marshall, P.A., Groy, T.L., Van Der Vaart, A., Ziller, J.W., Furmick, J.K., Graeber, M.E., Matro, E., Miguel, B.V. (2009). Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: Novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl) ethynyl] benzoic acid (bexarotene). *J. Med. Chem.*, **52**(5950–5966).
111. Wang, T.Y., Li, Q., Bi, K.-S. (2017). Bioactive flavonoids in medicinal plants: Structure, activity and biological fate. *Asian J. Pharm. Sci.*, **12**(305–314).
112. Patil, V.M., Masand, N. (2019). Anticancer potential of flavonoids: Chemistry, biological activities, and future perspectives. In: Rahman, A., editor. *Studies in Natural Products Chemistry*, 1st ed. Volume 59. Elsevier; Amsterdam, The Netherlands: pp. 401–430.
113. Silalahi, J. (2002). Anticancer and health protective properties of citrus fruit components. *Asia Pacific J. Clin. Nutr.*, **11**(79–84).
114. Darband, S.G., Kaviani, M., Yousefi, B., Sadighparvar, S., Pakdel, F.G., Attari, J.A., Mohebbi, I., Naderi, S., Majidinia, M. (2018). Quercetin: A functional dietary flavonoid with potential chemo-preventive properties in colorectal cancer. *J. Cell. Physiol.*, **233**(6544–6560).
115. Yang, P.-W., Lu, Z.-Y., Pan, Q., Chen, T.-T., Feng, X.-J., Wang, S.-M., Pan, Y.-C., Zhu, M.-H., Zhang, S.-H. (2019). MicroRNA-6809–5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1. *Phytomedicine*, **57**(18–29).
116. Chen, A.Y., Chen, Y.C. (2013). A review of the dietary flavonoid, kaempferol on human health and cancer chemoprevention. *Food Chem.*, **138**(2099–2107).
117. Devi, K.P., Rajavel, T., Nabavi, S.F., Setzer, W.N., Ahmadi, A., Mansouri, K., Nabavi, S.M. (2015). Hesperidin: A promising anticancer agent from nature. *Ind. Crops Prod.*, **76**(582–589).
118. Ersoz, M., Erdemir, A., Duranoglu, D., Uzunoglu, D., Arasoglu, T., Derman, S., Mansuroglu, B. (2019). Comparative evaluation of hesperetin loaded nanoparticles for anticancer activity against C6 glioma cancer cells. *Artificial Cells Nanomed. Biotechnol.*, **47**(319–329).
119. Alsayari, A., Muhsinah, A.B., Hassan, M.Z., Ahsan, M.J., Alshehri, J.A., Begum, N. (2019). Aurone: A biologically attractive scaffold as anticancer agent. *European J. Med. Chem.*, **166**(417–431).
120. Devi, K.P., Rajavel, T., Habtemariam, S., Nabavi, S.F., Nabavi, S.M. (2015). Molecular mechanisms underlying anticancer effects of myricetin. *Life Sci.*, **142**(19–25).
121. Al-Dabbagh, B., Elhaty, I.A., Elhaw, M., Murali, C., Al Mansoori, A., Awad, B., Amin, A. (2019). Antioxidant and anticancer activities of chamomile (*Matricaria recutita* L.). *BMC Res. Notes*, **12**(3).
122. Shahat, A.A., Hidayathulla, S., Khan, A.A., Alanazi, A.M., Al Meanazel, O.T., Alqahtani, A.S., Alsaied, M.S., Hussein, A.A. (2019). Phytochemical profiling, antioxidant and anticancer activities of *Gastrocotyle hispida* growing in Saudi Arabia. *Acta Trop.*, **191**(243–247).
123. Wang, Q.-H., Guo, S., Yang, X.-Y., Zhang, Y.-F., Shang, M.-Y., Shang, Y.-H., Xiao, J.-J., Cai, S.-Q. (2017). Flavonoids isolated from *Sinopodophylli Fructus* and their bioactivities against human breast cancer cells. *Chin. J. Nat. Med.*, **15**(225–233).
124. Bailly, C. (2020). Molecular and cellular basis of the anticancer activity of the prenylated flavonoid icaritin in hepatocellular carcinoma. *Chem. Interact.*, **325**(109124).

125. Zwicker, J. (2019). Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. *JCI Insight*, **4**(4).
126. Cancer Statistics Review, 1975–2013-Previous Version-SEER Cancer Statistics Review. Available online: [https://seer.cancer.gov/archive/csr/1975\\_2013/index.html](https://seer.cancer.gov/archive/csr/1975_2013/index.html) (accessed on 11 May 2025).
127. Yang, K., Oak, A.S.W., Slominski, R.M., Brożyna, A.A., Slominski, A.T. (2020). Current molecular markers of melanoma and treatment targets. *Int. J. Mol. Sci.*, **21**(3535).
128. Keung, E.Z., Gershenwald, J.E. (2018). The Eighth Edition American Joint Committee on Cancer (AJCC) Melanoma Staging System: Implications for melanoma treatment and care. *Expert Rev. Anticancer Ther.*, **18**(775–784).
129. Melis, C., Rogiers, A., Bechter, O., van den Oord, J.J. (2017). Molecular genetic and immunotherapeutic targets in metastatic melanoma. *Virchows Arch.*, **471**(281–293).
130. Raman, M., Chen, W., Cobb, M.H. (2007). Differential regulation and properties of MAPKs. *Oncogene*, **26**(3100–3112).
131. Menzies, A.M., Haydu, L.E., Visintin, L., Carlino, M.S., Howle, J.R., Thompson, J.F., Kefford, R.F., Scolyer, R.A., Long, G.V. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. *Clin. Cancer Res.*, **18**(3242–3249).
132. Forman V., Haladová M., Grančai D., Ficková M. (2015). Antiproliferative activities of water infusions from leaves of five *Cornus* L. species. *Molecules*. **20**(12):22546-52.
133. Bussmann R.W., Sharon D. (2006). Traditional medicinal plant use in Northern Peru: tracking two thousand years of healing culture. *J Ethnobiol Ethnomed*. **2**:47.
134. Sandoval T.A., Urueña C.P., Llano M., Gómez-Cadena A., Hernández J.F., Sequeda L.G., et al. (2016). Standardized extract from *Caesalpinia spinosa* is cytotoxic over cancer stem cells and enhances anticancer activity of doxorubicin. *Am J Chin Med*. **44**(8):1693-717.
135. Zhang B.M., Wang Z.B., Xin P., Wang Q.H., Bu H., Kuang H.X. (2018). Phytochemistry and pharmacology of genus *Ephedra*. *Chin J Nat Med*. **16**(11):811-28.
136. Schäfer S., Salcher S., Seiter M., Ranninger C., Möst M., Obexer P., et al. (2016). Characterization of the XIAP-inhibiting proanthocyanidin fraction of the aerial parts of *Ephedra sinica*. *Planta Med*. **82**(11-12):973-85.
137. Hatami E. (2018). Tannic acid-lung fluid assemblies promote interaction and delivery of drugs to lung cancer cells. *Pharmaceutics*. **10**:111.
138. Liu L. (2020). Polymeric nanoparticles of poly (2-oxazoline), tannic acid and doxorubicin for controlled release and cancer treatment. *Chin Chem Lett*. **31**:501-504.
139. Huang Y. (2019). Coordination driven self-assembly for enhancing the biological stability of nobiletin. *J Mol Liq*. **292**:111420.
140. Kuo P.L., Lin T.C., Lin C.C. (2002). The antiproliferative activity of aloe-emodin is through p53-dependent and p21-dependent apoptotic pathway in human hepatoma cell lines. *Life Sci*. **71**(16):1879–1892.
141. Guo J.M., Xiao B.X., Liu Q., Zhang S., Liu D.H., Gong Z.H. (2007). Anti-cancer effect of aloe-emodin on cervical cancer cells involves G2/M arrest and induction of differentiation. *Acta Pharmacol Sin*. **28**(12):1991–1995.
142. Xiao B., Guo J., Liu D., Zhang S. (2007). Aloe-emodin induces in vitro G2/M arrest and alkaline phosphatase activation in human oral cancer KB cells. *Oral Oncol*. **43**(9):905–910.
143. Guo J., Xiao B., Liu Q., Gong Z., Le Y. (2008). Suppression of C-myc expression associates with anti-proliferation of aloe-emodin on gastric cancer cells. *Cancer Investig*. **26**(4):369–374.
144. Chiu T.H., Lai W.W., Hsia T.C., Yang J.S., Lai T.Y., Wu P.P., Ma C.Y., Yeh C.C., Ho C.C., Lu H.F., Wood W.G., Chung J.G. (2009). Aloe-emodin induces cell death through S-phase arrest and caspase-dependent pathways in human tongue squamous cancer SCC-4 cells. *Anticancer Res*. **29**(11):4503–4511.
145. Lee H.Z., Lin C.J., Yang W.H., Leung W.C., Chang S.P. (2006). Aloe-emodin-induced DNA damage through generation of reactive oxygen species in human lung carcinoma cells. *Cancer Lett*. **239**(1):55–63.
146. Yeh F.T., Wu C.H., Lee H.Z. (2003). Signaling pathway for aloe-emodin-induced apoptosis in human H460 lung non-small carcinoma cell. *Int J Cancer*. **106**(1):26–33.
147. Pecere T., Sarinella F., Salata C., Gatto B., Bet A., Dalla V.F., Diaspro A., Carli M., Palumbo M., Palu G. (2003). Involvement of p53 in specific antineuroectodermal tumor activity of aloe-emodin. *Int J Cancer*. **106**(6):836–847.

- 
148. Lin C.C., Chao P.Y., Shen C.Y., Shu J.J., Yen S.K., Huang C.Y. (2014). Novel target genes responsive to apoptotic activity by *Ocimum gratissimum* in human osteosarcoma cells. *Am J Clin Med.* **42**(3):743–767.
  149. Tabolacci C., Lentini A., Mattioli P., Provenzano B., Oliverio S., Carlomosti F., Beninati S. (2010). Antitumor properties of aloe-emodin and induction of transglutaminase 2 activity in B16-F10 melanoma cells. *Life Sci.* **87**(9-10):316–324.
  150. Suboj P., Babykutty S., Valiyaparambil G.D.R., Nair R.S., Srinivas P., Gopala S. (2012). Aloe-emodin inhibits colon cancer cell migration/angiogenesis by downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-kappaB. *Eur J Pharm Sci.* **45**(5):581–591.
  151. Hyun J.W., Kun-Young P., Chung-Ho R., Won H.L., Byung T.C., Gi Y.K., Yeong-Min P., Yung H.C. (2006).  $\beta$ -Lapachone, a quinone isolated from *Tabebuia avellanae*, induces apoptosis in HepG2 Hepatoma cell line through induction of Bax and activation of caspase. *J Med Food.* **9**(2):161–168.